Processa Pharmaceuticals Reports Increased Net Loss of $3.4 Million in Q1 2026

Processa Pharmaceuticals, Inc. reported a net loss of $3.4 million for the first quarter of 2026, an increase from a net loss of $2.8 million during the same period in 2025. The company's operating loss also rose to $3.3 million, compared to $2.8 million in the prior year. The increase in losses is attributed to higher research and development expenses, which grew by approximately $221,000 to $1.8 million, primarily due to increased professional fees associated with the ongoing Phase 2 clinical trial for its Next Generation Cancer therapy, NGC-Cap. General and administrative expenses also increased by $264,000 to $1.5 million, driven by higher professional fees and insurance costs.

As of March 31, 2026, Processa's total assets were reported at $4.5 million, a significant decrease from $7.8 million at the end of 2025. This decline was largely due to a reduction in cash and cash equivalents, which fell to $1.7 million from $5.5 million. The company's accumulated deficit reached $104.2 million, reflecting its ongoing investment in research and development without any product revenue to date. The company has not yet achieved profitability and does not expect positive cash flow from operations in the foreseeable future.

In terms of financing activities, Processa raised approximately $245,000 through the issuance of common stock during the first quarter of 2026. This included a private placement transaction in February and additional purchases by directors and employees. The company also plans to continue seeking additional funding through various means, including public or private equity offerings and strategic partnerships, to support its ongoing clinical trials and operational needs. The management indicated that without further funding, the current cash reserves may not be sufficient to sustain operations for the next year.

Operationally, Processa is focused on advancing its oncology pipeline, which includes NGC-Cap and NGC-Iri, with NGC-Cap currently in a Phase 2 trial. The company has enrolled the required number of patients for the first interim analysis, expected to be completed in the first half of 2026. The company is also exploring options for its non-oncology drugs, which may include out-licensing opportunities. The management's outlook remains cautious, emphasizing the need for additional capital to continue its research and development efforts and meet its operational commitments.

Overall, Processa Pharmaceuticals continues to navigate a challenging financial landscape as it invests heavily in the development of its cancer therapies while facing significant operational losses and a reliance on external funding to sustain its business activities.